New/NN
Lung/NN
Cancer/NN
Panel/NN
for/IN
High-Throughput/JJ
Targeted/VBN
Resequencing/VBG
./.
====================
We/PRP
present/VBP
a/DT
new/JJ
next-generation/NN
sequencing-based/VBN
method/NN
to/TO
identify/VB
somatic/JJ
mutations/NNS
of/IN
lung/NN
cancer/NN
./.
====================
It/PRP
is/VBZ
a/DT
comprehensive/JJ
mutation/NN
profiling/VBG
protocol/NN
to/TO
detect/VB
somatic/JJ
mutations/NNS
in/IN
30/CD
genes/NNS
found/VBN
frequently/RB
in/IN
lung/NN
adenocarcinoma/NN
./.
====================
The/DT
total/JJ
length/NN
of/IN
the/DT
target/NN
regions/NNS
is/VBZ
107/CD
kb/NN
,/,
and/CC
a/DT
capture/JJ
assay/NN
was/VBD
designed/VBN
to/TO
cover/VB
99/CD
%/NN
of/IN
it/PRP
./.
====================
This/DT
method/NN
exhibited/VBD
about/RB
97/CD
%/NN
mean/JJ
coverage/NN
at/IN
30×/CD
sequencing/NN
depth/NN
and/CC
42/CD
%/NN
average/NN
specificity/NN
when/WRB
sequencing/NN
of/IN
more/RBR
than/IN
3.25/CD
Gb/NN
was/VBD
carried/VBN
out/RP
for/IN
the/DT
normal/JJ
sample/JJ
./.
====================
We/PRP
discovered/VBD
513/CD
variations/NNS
from/IN
targeted/VBN
exome/JJ
sequencing/NN
of/IN
lung/NN
cancer/NN
cells/NNS
,/,
which/WDT
is/VBZ
3.9-fold/JJ
higher/JJR
than/IN
in/IN
the/DT
normal/JJ
sample/JJ
./.
====================
The/DT
variations/NNS
in/IN
cancer/NN
cells/NNS
included/VBD
previously/RB
reported/VBD
somatic/JJ
mutations/NNS
in/IN
the/DT
COSMIC/NN
database/NN
,/,
such/JJ
as/IN
variations/NNS
in/IN
TP53/NN
,/,
KRAS/JJ
,/,
and/CC
STK11/NN
of/IN
sample/JJ
H-23/NN
and/CC
in/IN
EGFR/NN
of/IN
sample/JJ
H-1650/NN
,/,
especially/RB
with/IN
more/RBR
than/IN
1,000×/NN
coverage/NN
./.
====================
Among/IN
the/DT
somatic/JJ
mutations/NNS
,/,
up/IN
to/TO
91/CD
%/NN
of/IN
single/JJ
nucleotide/NN
polymorphisms/NNS
from/IN
the/DT
two/CD
cancer/NN
samples/NNS
were/VBD
validated/VBN
by/IN
DNA/NN
microarray-based/VBN
genotyping/VBG
./.
====================
Our/PRP$
results/NNS
demonstrated/VBD
the/DT
feasibility/NN
of/IN
high-throughput/JJ
mutation/NN
profiling/VBG
with/IN
lung/NN
adenocarcinoma/NN
samples/NNS
,/,
and/CC
the/DT
profiling/VBG
method/NN
can/MD
be/VB
used/VBN
as/IN
a/DT
robust/JJ
and/CC
effective/JJ
protocol/NN
for/IN
somatic/JJ
variant/JJ
screening/NN
./.
====================
Non-small-cell/JJ
lung/NN
cancer/NN
is/VBZ
an/DT
increasingly/RB
common/JJ
and/CC
lethal/JJ
disease/NN
,/,
accounting/VBG
for/IN
25/CD
%/NN
of/IN
all/DT
cancer/NN
deaths/NNS
./.
====================
Sequencing/NN
of/IN
the/DT
lung/NN
cancer/NN
genome/NN
is/VBZ
of/IN
particular/JJ
interest/NN
for/IN
identifying/VBG
driver/RB
mutations/NNS
and/CC
their/PRP$
pathways/NNS
involved/VBN
in/IN
cancer/NN
growth/NN
and/CC
development/NN
[/(
1/CD
]/)
./.
====================
Somatic/JJ
mutational/JJ
profiles/NNS
are/VBP
crucial/JJ
for/IN
cancer/NN
diagnosis/NN
and/CC
classification/NN
,/,
which/WDT
lead/VBP
to/TO
tailoring/VBG
the/DT
best/JJS
therapeutic/JJ
strategy/NN
to/TO
individual/JJ
patients/NNS
[/(
2/CD
]/)
./.
====================
Previous/JJ
studies/NNS
using/VBG
the/DT
Sanger/NN
sequencing/NN
method/NN
have/VBP
identified/VBN
several/JJ
key/JJ
mutations/NNS
associated/VBN
with/IN
lung/NN
cancer/NN
./.
====================
Massive/JJ
PCR/NN
amplification/NN
and/CC
Sanger/NN
sequencing/NN
of/IN
623/CD
candidate/NN
cancer/NN
genes/NNS
in/IN
188/CD
lung/NN
adenocarcinomas/NNS
discovered/VBN
26/CD
mutational/JJ
target/NN
genes/NNS
[/(
3/CD
]/)
./.
====================
Although/IN
the/DT
study/NN
provided/VBD
highly/RB
valuable/JJ
results/NNS
,/,
it/PRP
is/VBZ
very/RB
time-consuming/JJ
and/CC
costly-so/RB
much/RB
so/RB
that/IN
a/DT
single/JJ
laboratory/NN
can/MD
hardly/RB
perform/NN
this/DT
kind/NN
of/IN
large-scale/JJ
sequencing/NN
projects/NNS
./.
====================
A/DT
mass/NN
spectrometric-based/VBN
mutation/NN
detection/NN
technology/NN
,/,
named/VBN
OncoMap/NN
,/,
has/VBZ
been/VBN
effective/JJ
in/IN
identifying/VBG
somatic/JJ
mutations/NNS
in/IN
cancer/NN
genomes/NNS
[/(
4/CD
]/)
./.
====================
Currently/RB
,/,
it/PRP
can/MD
detect/VB
more/RBR
than/IN
1,000/CD
mutations/NNS
in/IN
112/CD
commonly/RB
mutated/VBN
genes/NNS
that/WDT
were/VBD
previously/RB
identified/VBN
as/IN
oncogenes/NNS
and/CC
tumor/NN
suppressors/NNS
[/(
5/CD
]/)
./.
====================
Although/IN
OncoMap/NN
is/VBZ
a/DT
high-throughput/JJ
method/NN
for/IN
mutational/JJ
profiling/VBG
with/IN
both/DT
fresh/JJ
frozen/VBN
and/CC
paraffin-embedded/JJ
tissue/NN
samples/NNS
,/,
the/DT
mutation/NN
detection/NN
is/VBZ
limited/JJ
to/TO
previously/RB
identified/VBN
mutations/NNS
,/,
and/CC
it/PRP
can/MD
not/RB
discover/RB
novel/JJ
mutations/NNS
./.
====================
Recent/JJ
advancements/NNS
of/IN
next-generation/NN
sequencing/NN
technology/NN
have/VBP
made/VBN
breakthroughs/NNS
in/IN
identifying/VBG
unknown/JJ
somatic/JJ
mutations/NNS
[/(
6/CD
]/)
./.
====================
Combined/JJ
with/IN
sequencing/NN
technology/NN
,/,
targeted/VBN
enrichment/JJ
techniques/NNS
have/VBP
been/VBN
developed/VBN
to/TO
reduce/VB
sequencing/NN
cost/JJS
and/CC
time/NN
[/(
7/CD
]/)
./.
====================
Several/JJ
recent/JJ
studies/NNS
have/VBP
reported/VBN
targeted/VBN
resequencing/VBG
of/IN
cancer/NN
samples/NNS
using/VBG
next-generation/JJ
sequencing/NN
technologies/NNS
[/(
8/CD
,/,
9/CD
]/)
./.
====================
Here/RB
,/,
we/PRP
present/VBP
a/DT
fast/JJ
and/CC
cost-effective/JJ
method/NN
to/TO
identify/VB
somatic/JJ
mutations/NNS
in/IN
lung/NN
cancer/NN
./.
====================
We/PRP
surveyed/VBD
the/DT
literature/NN
and/CC
chose/NN
30/CD
mutational/JJ
target/NN
genes/NNS
that/WDT
were/VBD
associated/VBN
strongly/RB
with/IN
lung/NN
adenocarcinoma/NN
development/NN
./.
====================
Target/NN
gene/NN
capture/NN
was/VBD
performed/VBN
using/VBG
selector/NN
probes/NNS
,/,
which/WDT
involved/VBD
circularization/NN
and/CC
amplification/NN
of/IN
specific/JJ
restriction/NN
fragments/NNS
covering/VBG
the/DT
target/NN
genes/NNS
using/VBG
rolling/NN
circle/NN
amplification/NN
[/(
10/CD
]/)
./.
====================
The/DT
captured/JJ
target/NN
DNAs/NNS
were/VBD
analyzed/VBN
by/IN
next-generation/NN
sequencing/NN
to/TO
find/VB
somatic/JJ
variations/NNS
./.
====================
This/DT
method/NN
could/MD
be/VB
useful/JJ
to/TO
detect/VB
previously/RB
known/VBN
recurrent/JJ
mutations/NNS
as/IN
well/RB
as/IN
novel/JJ
variations/NNS
./.
====================
Preparation/NN
of/IN
genomic/JJ
DNA/NN
from/IN
cancer/NN
cell/NN
lines/NNS
====================
We/PRP
ordered/VBD
normal/JJ
genomic/JJ
DNA/NN
sample/NN
from/IN
the/DT
Coriell/NN
Institute/JJ
Cell/NN
Repository/NN
(/(
CCR/NN
ID/NN
NA17022/NN
;/:
Camden/NNP
,/,
NJ/NNP
,/,
USA/NNP
)/)
,/,
which/WDT
originated/VBD
from/IN
a/DT
normal/JJ
Caucasian/JJ
male/JJ
of/IN
European/JJ
descent/JJ
./.
====================
For/IN
cancer/NN
genomic/JJ
DNAs/NNS
,/,
H-1650/NN
and/CC
H-23/NN
cancer/NN
cells/NNS
were/VBD
cultured/VBN
and/CC
harvested/VBD
for/IN
DNA/NN
preparation/NN
./.
====================
Genomic/JJ
DNA/NN
(/(
gDNA/NN
)/)
was/VBD
extracted/VBN
with/IN
the/DT
QIAamp/NN
DNA/NN
blood/NN
kit/NN
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
(/(
Qiagen/NN
,/,
Hilden/JJ
,/,
Germany/NNP
)/)
./.
====================
The/DT
DNA/NN
quality/NN
and/CC
quantity/NN
were/VBD
assessed/VBN
with/IN
the/DT
use/NN
of/IN
a/DT
Nanodrop/JJ
spectrophotometer/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
,/,
Wilmington/JJ
,/,
DE/NN
,/,
USA/NN
)/)
./.
====================
Design/IN
and/CC
oligonucleotides/NNS
====================
The/DT
list/NN
of/IN
the/DT
entire/JJ
exons/NNS
for/IN
the/DT
30/CD
genes/NNS
was/VBD
obtained/VBN
from/IN
a/DT
consensus/NN
coding/VBG
sequence/NN
database/NN
,/,
CCDS/NN
(/(
build/JJ
36.3/CD
)/)
,/,
showing/VBG
a/DT
total/JJ
number/NN
of/IN
701/CD
exons/NNS
covering/VBG
102/CD
kb/NN
,/,
according/VBG
to/TO
hg18/CD
(/(
March/NNP
,/,
2006/CD
assembly/RB
)/)
./.
====================
Targeted/VBN
restriction/NN
fragments/NNS
were/VBD
selected/VBN
using/VBG
Disperse/JJ
software/JJ
[/(
11/CD
]/)
./.
====================
Templates/NNS
for/IN
circularization/NN
of/IN
each/DT
chosen/NN
targeted/VBN
fragment/NN
(/(
selector/NN
probes/NNS
)/)
were/VBD
designed/VBN
using/VBG
ProbeMaker/NN
software/JJ
[/(
12/CD
]/)
./.
====================
Each/DT
selector/NN
probe/NN
consisted/VBD
of/IN
two/CD
sequences/NNS
of/IN
20-25/CD
nucleotides/NNS
complementary/JJ
to/TO
the/DT
ends/NNS
of/IN
its/PRP$
targeted/VBN
restriction/NN
fragment/NN
./.
====================
The/DT
3'-biotin-labeled/JJ
oligonucleotides/NNS
(/(
Integrated/JJ
DNA/NN
Technologies/NNS
,/,
Coralville/NN
,/,
IA/NN
,/,
USA/NNP
)/)
were/VBD
prepared/VBN
by/IN
incubating/VBG
the/DT
oligonucleotides/NNS
with/IN
1×/CD
Tdt/NNP
buffer/NN
(/(
NEB/NN
)/)
,/,
1×/CD
CoCl2/NN
(/(
NEB/NN
)/)
,/,
0.1/CD
mM/NN
dUTP-biotin/NN
(/(
Roche/NNP
Diagnostics/NNS
,/,
Mannheim/NNP
,/,
Germany/NNP
)/)
,/,
and/CC
0.2/CD
units/µL/JJ
terminal/JJ
transferase/NN
(/(
NEB/NN
)/)
in/IN
a/DT
final/JJ
volume/NN
of/IN
50/CD
µL/NNS
./.
====================
The/DT
reaction/NN
was/VBD
incubated/VBN
at/IN
37℃/CD
for/IN
1/CD
h/NN
and/CC
followed/VBN
by/IN
enzyme/NN
inactivation/NN
at/IN
75℃/CD
for/IN
20/CD
min/NN
./.
====================
Target/NN
enrichment/JJ
====================
Eight/CD
different/JJ
restriction/NN
reactions/NNS
were/VBD
used/VBN
to/TO
digest/VB
genomic/JJ
DNAs/NNS
from/IN
each/DT
sample/JJ
,/,
including/VBG
SfcI/JJ
and/CC
Hpy188I/NNP
in/IN
NEB/NN
buffer/CC
4/CD
;/:
DdeI/RB
and/CC
AluI/RB
in/IN
NEB/NN
buffer/CC
2/CD
;/:
MseI/NNP
and/CC
Bsu36I/NNP
in/IN
NEB/NN
buffer/CC
3/CD
;/:
MslI/NNP
and/CC
BfaI/NN
in/IN
NEB/NN
buffer/CC
4/CD
;/:
HpyCH4III/RB
and/CC
Bsp1286/FW
in/IN
NEB/NN
buffer/CC
4/CD
;/:
SfcI/NNP
and/CC
NlaIII/RB
in/IN
NEB/NN
buffer/CC
4/CD
;/:
MseI/NNP
and/CC
HpyCH4III/RB
in/IN
NEB/NN
buffer/CC
4/CD
;/:
and/CC
HpyCH4V/JJ
and/CC
EcoO109I/NN
in/IN
NEB/NN
buffer/CC
4/CD
(/(
New/JJ
England/CC
Biolabs/NNP
,/,
Ipswich/JJ
,/,
MA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
restriction/NN
reactions/NNS
contained/VBD
1/CD
unit/NN
each/DT
of/IN
two/CD
restriction/NN
enzymes/NNS
and/CC
their/PRP$
corresponding/JJ
compatible/JJ
NEB/NN
buffer/NN
in/IN
1×/CD
concentration/NN
and/CC
0.85/CD
µg/µL/NN
bovine/JJ
serum/NN
albumin/NN
(/(
BSA/NN
)/)
in/IN
a/DT
total/JJ
volume/NN
of/IN
10/CD
µL/NN
./.
====================
The/DT
reactions/NNS
were/VBD
incubated/VBN
at/IN
37℃/CD
for/IN
60/CD
min/NN
,/,
followed/VBN
by/IN
enzyme/NN
inactivation/NN
at/IN
80℃/CD
for/IN
20/CD
min/NN
./.
====================
A/DT
total/JJ
of/IN
80/CD
µL/NN
of/IN
pooled/JJ
digested/JJ
sample/NN
was/VBD
mixed/VBN
with/IN
10/CD
pM/NN
biotinylated/VBN
selector/NN
probes/NNS
,/,
1/CD
M/NN
NaCl/NN
,/,
10/CD
mM/NN
Tris-HCl/NN
(/(
pH/NN
7.5/CD
)/)
,/,
5/CD
mM/NN
EDTA/NN
,/,
and/CC
0.1/CD
%/NN
Tween-20/CD
in/IN
a/DT
total/JJ
volume/NN
of/IN
160/CD
µL/NN
./.
====================
The/DT
mixture/NN
was/VBD
incubated/VBN
and/CC
hybridized/VBD
at/IN
95℃/CD
for/IN
10/CD
min/NN
,/,
75℃/RB
for/IN
30/CD
min/NN
,/,
68℃/RB
for/IN
30/CD
min/NN
,/,
55℃/RB
for/IN
30/CD
min/NN
,/,
and/CC
46℃/RB
for/IN
10/CD
h./RB
The/DT
hybridized/VBN
solution/NN
was/VBD
mixed/VBN
with/IN
10/CD
µL/JJ
M-280/CD
streptavidin-coated/JJ
magnetic/JJ
beads/VBZ
(/(
3.35/CD
×/RB
107/CD
beads/mL/IN
;/:
Invitrogen/NN
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
in/IN
1/CD
M/NN
NaCl/NN
,/,
10/CD
mM/NN
Tris-HCl/NNP
(/(
pH/NN
7.5/CD
)/)
,/,
1/LS
mM/NN
EDTA/NN
,/,
and/CC
0.1/CD
%/NN
Tween-20/CD
in/IN
a/DT
final/JJ
volume/NN
of/IN
200/CD
µL/RB
and/CC
incubated/VBN
at/IN
room/JJ
temperature/NN
for/IN
10/CD
min/NN
./.
====================
After/IN
incubation/NN
,/,
the/DT
beads/VBZ
were/VBD
collected/VBN
using/VBG
a/DT
ring/NN
magnet/NN
and/CC
washed/VBD
in/IN
1/CD
M/NN
NaCl/NN
,/,
10/CD
mM/NN
Tris-HCl/NN
(/(
pH/NN
7.5/CD
)/)
,/,
5/CD
mM/NN
EDTA/NN
,/,
and/CC
0.1/CD
%/NN
Tween-20/CD
in/IN
a/DT
total/JJ
volume/NN
of/IN
200/CD
µL/NN
at/IN
46℃/CD
for/IN
30/CD
min/NN
with/IN
rotation/NN
./.
====================
Multiple/JJ
displacement/NN
amplification/NN
====================
Genomic/JJ
fragments/NNS
were/VBD
circularized/VBN
by/IN
incubating/VBG
the/DT
beads/VBZ
with/IN
1×/CD
Ampligase/NN
reaction/NN
buffer/NN
,/,
0.25/CD
U/µL/NN
Ampligase/NN
(/(
Epicentre/JJ
,/,
Madison/NNP
,/,
WI/NN
,/,
USA/NNP
)/)
,/,
and/CC
0.1/CD
µg/µL/NN
BSA/NN
in/IN
a/DT
total/JJ
volume/NN
of/IN
50/CD
µL/NNS
at/IN
55℃/CD
for/IN
10/CD
min/NN
./.
====================
The/DT
circularized/VBN
molecules/NNS
were/VBD
separated/VBN
from/IN
the/DT
beads/VBZ
by/IN
incubation/NN
with/IN
5/CD
µL/NN
sample/NN
buffer/NN
at/IN
95℃/CD
for/IN
10/CD
min/NN
and/CC
collected/JJ
with/IN
a/DT
ring/NN
magnet/NN
rack/NN
./.
====================
The/DT
supernatant/JJ
was/VBD
incubated/VBN
with/IN
5/CD
µL/NN
reaction/NN
buffer/NN
and/CC
0.2/CD
µL/NN
enzyme/NN
mix/JJ
(/(
Templiphi/NNP
;/:
GE/NNP
Life/NN
Sciences/NNS
,/,
Piscataway/NN
,/,
NJ/NNP
,/,
USA/NNP
)/)
at/IN
30℃/CD
for/IN
4/CD
h/NN
,/,
followed/VBN
by/IN
inactivation/NN
at/IN
65℃/CD
for/IN
10/CD
min/NN
./.
====================
Real-time/NN
quantitative/JJ
PCR/NN
analysis/NN
====================
The/DT
enriched/JJ
samples/NNS
were/VBD
analyzed/VBN
with/IN
real-time/NN
quantitative/JJ
PCR/NN
(/(
qPCR/NN
)/)
and/CC
DNA/NN
quantification/NN
to/TO
evaluate/VB
enrichment/JJ
bias/NNS
and/CC
specificity/NN
./.
====================
PCR/NN
primers/NNS
were/VBD
placed/VBN
randomly/RB
in/IN
the/DT
targeted/VBN
regions/NNS
and/CC
quality/NN
controlled/VBN
using/VBG
standard/JJ
genomic/JJ
DNA/NN
./.
====================
The/DT
qPCR/NN
results/NNS
were/VBD
used/VBN
to/TO
estimate/VB
how/WRB
much/RB
target/NN
DNA/NN
was/VBD
present/JJ
in/IN
the/DT
amplification/NN
products/NNS
,/,
and/CC
then/RB
,/,
the/DT
specificity/NN
(/(
proportion/NN
target/NN
material/JJ
)/)
was/VBD
estimated/VBN
by/IN
measuring/VBG
the/DT
amount/NN
of/IN
DNA/NN
in/IN
the/DT
reactions/NNS
./.
====================
The/DT
enriched/JJ
and/CC
pre-enriched/VBD
control/JJ
DNAs/NNS
were/VBD
diluted/VBN
(/(
final/JJ
dilution/NN
1:3,600/CD
)/)
in/IN
a/DT
PCR/NN
mix/JJ
containing/VBG
1×/CD
PCR/NN
buffer/NN
,/,
2/CD
mM/NN
MgCl2/NN
,/,
1/CD
unit/NN
Platinum/NN
Taq/NN
,/,
0.2/CD
mM/NN
dNTP/NN
(/(
10297-018/CD
;/:
Invitrogen/NN
)/)
,/,
1×/CD
SYBR/NN
Green/NNP
I/NN
,/,
10/CD
%/NN
DMSO/NN
,/,
and/CC
0.16/CD
µM/RB
of/IN
either/CC
on-target/JJ
primer/NN
or/CC
off-target/IN
primer/NN
to/TO
a/DT
total/JJ
volume/NN
of/IN
30/CD
µL/NN
./.
====================
The/DT
genomic/JJ
reference/NN
DNA/NN
was/VBD
10/CD
ng/NN
of/IN
template/NN
in/IN
the/DT
same/JJ
PCR/NN
mixture/NN
as/IN
described/VBN
above/IN
./.
====================
The/DT
qPCR/NN
was/VBD
performed/VBN
using/VBG
an/DT
LC480/NN
Real-Time/NN
PCR/NN
system/NN
(/(
Roche/NNP
)/)
,/,
and/CC
the/DT
conditions/NNS
were/VBD
as/IN
follows/VBZ
:/:
95℃/CD
for/IN
5/CD
min/NN
followed/VBN
by/IN
40/CD
cycles/NNS
of/IN
(/(
95℃/CD
15/CD
s/NNS
,/,
56℃/CD
30/CD
s/NNS
)/)
,/,
with/IN
end-point/JJ
measurement/NN
of/IN
the/DT
fluorescence/NN
after/IN
each/DT
completed/VBN
cycle/NN
./.
====================
Library/JJ
preparation/NN
and/CC
massive/JJ
parallel/NN
sequencing/NN
====================
Libraries/NNS
were/VBD
prepared/VBN
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
(/(
Illumina/NN
,/,
San/JJ
Diego/NN
,/,
CA/NN
,/,
USA/NN
)/)
./.
====================
Briefly/RB
,/,
5/CD
µg/NN
of/IN
gDNA/JJ
in/IN
200/CD
µL/NN
nuclease-free/JJ
water/NN
was/VBD
fragmented/JJ
by/IN
a/DT
Bioruptor/NN
(/(
Diagenode/NN
,/,
Liege/JJ
,/,
Belgium/NN
)/)
at/IN
high/JJ
power/JJR
for/IN
30/CD
min/NN
(/(
30/CD
s/NNS
ON/NN
and/CC
30/CD
s/NNS
OFF/NN
)/)
./.
====================
Overhangs/NNS
of/IN
fragmented/JJ
gDNA/NN
were/VBD
converted/VBN
to/TO
blunt/VB
ends/NNS
using/VBG
T4/NN
DNA/NN
ligase/NN
and/CC
Klenow/NN
enzyme/NN
./.
====================
Subsequently/RB
,/,
an/DT
'/``
A/NN
'/``
base/NN
was/VBD
added/VBN
to/TO
the/DT
ends/NNS
of/IN
double-stranded/JJ
DNA/NN
using/VBG
Klenow/JJ
exo-/JJ
(/(
3/CD
'/``
to/TO
5/CD
'/``
exo/NN
minus/JJ
)/)
./.
====================
The/DT
paired-end/NN
adaptor/NN
(/(
Illumina/NN
)/)
with/IN
a/DT
single/JJ
'T/NN
'/``
base/NN
overhang/VBG
at/IN
the/DT
3/CD
'/``
end/NN
was/VBD
ligated/VBN
to/TO
the/DT
products/NNS
above/IN
./.
====================
The/DT
PE/NN
adaptor-ligated/VBN
products/NNS
were/VBD
separated/VBN
on/IN
a/DT
2/CD
%/NN
agarose/IN
gel/NN
and/CC
excised/VBN
from/IN
the/DT
gel/NN
from/IN
approximately/RB
400/CD
bp/NN
to/TO
500/CD
bp/NN
./.
====================
The/DT
sequencing/NN
libraries/NNS
were/VBD
bar-coded/VBN
to/TO
allow/VB
sequencing/NN
of/IN
6/CD
samples/NNS
in/IN
one/CD
lane/NN
of/IN
a/DT
flow/NN
cell/NN
./.
====================
Size-selected/JJ
DNA/NN
fragments/NNS
were/VBD
enriched/VBN
by/IN
PCR/NN
with/IN
PE/NN
primers/NNS
1.1/CD
and/CC
2.1/CD
(/(
Illumina/NN
)/)
./.
====================
The/DT
concentration/NN
of/IN
the/DT
libraries/NNS
was/VBD
measured/VBN
on/IN
both/CC
a/DT
Nanodrop/JJ
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
and/CC
Qubit/NN
IT/NN
(/(
Invitrogen/NN
)/)
./.
====================
Finally/RB
,/,
the/DT
libraries/NNS
were/VBD
validated/VBN
by/IN
a/DT
Bioanalyzer/JJ
(/(
Agilent/JJ
Technologies/NNS
,/,
Santa/NN
Clara/NN
,/,
CA/NN
,/,
USA/NN
)/)
./.
====================
The/DT
gDNA/JJ
library/NN
was/VBD
sequenced/VBN
using/VBG
the/DT
Illumina/NN
genome/NN
analyzer/NN
GAIIx/JJ
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
Short/NN
read/VBN
alignment/NN
and/CC
variation/NN
calling/VBG
====================
A/DT
total/JJ
of/IN
76-bp/JJ
paired-end/NN
or/CC
single-end/JJ
sequence/NN
reads/VBZ
with/IN
~200-bp/JJ
insert/NN
size/NN
were/VBD
aligned/VBN
to/TO
the/DT
human/JJ
reference/NN
genome/NN
(/(
NCBI/NN
build/JJ
37/CD
,/,
hg19/NN
)/)
with/IN
BWA/NN
algorithm1/NN
ver/RB
./.
====================
0.5.8c/CD
and/CC
default/NN
parameters/NNS
[/(
13/CD
]/)
./.
====================
Two/CD
mismatches/NNS
were/VBD
permitted/VBN
in/IN
a/DT
45-bp/JJ
seed/VBD
sequence/NN
./.
====================
Putative/JJ
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
and/CC
small/JJ
INDELs/NNS
were/VBD
called/VBN
by/IN
the/DT
pileup/NN
vcf/IN
function/NN
of/IN
Samtools/NNS
(/(
ver.0.1.9/CD
)/)
[/(
14/CD
]/)
./.
====================
The/DT
options/NNS
used/VBN
in/IN
filtering/VBG
variations/NNS
were/VBD
a/DT
minimum/JJ
of/IN
6/CD
for/IN
mapping/VBG
depth/NN
and/CC
quality/NN
threshold/JJ
of/IN
50/CD
for/IN
single/JJ
nucleotide/NN
variations/NNS
(/(
SNVs/NNS
)/)
and/CC
20/CD
for/IN
small/JJ
INDELs/NNS
./.
====================
Predicted/VBN
SNVs/NNS
were/VBD
compared/VBN
with/IN
NCBI/NN
dbSNP/NN
version/NN
131/CD
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/projects/SNP//JJ
)/)
to/TO
remove/VB
known/VBN
SNP/NN
information/NN
./.
====================
Non-synonymous/JJ
SNV/NN
information/NN
was/VBD
extracted/VBN
by/IN
comparing/VBG
UCSC/NN
(/(
http/NN
:/:
//genome.ucsc.edu//JJ
)/)
reference/VBP
gene/NN
information/NN
with/IN
the/DT
somatic/JJ
mutation/NN
list/NN
in/IN
the/DT
COSMIC/NN
cancer/NN
information/NN
database/NN
(/(
http/NN
:/:
//www.sanger.ac.uk/genetics/CGP/cosmic//JJ
)/)
./.
====================
PolyPhen/RB
(/(
polymorphism/NN
phenotyping/VBG
)/)
was/VBD
utilized/VBN
to/TO
predict/VB
possible/JJ
changes/NNS
in/IN
protein/NN
structure/NN
and/CC
function/NN
resulting/VBG
from/IN
a/DT
non-synonymous/JJ
amino/NN
acid/NN
change/NN
./.
====================
Genome-wide/NN
SNP/NN
analysis/NN
====================
SNP/NN
genotyping/VBG
was/VBD
performed/VBN
using/VBG
the/DT
Axiom/JJ
genotyping/VBG
solution/NN
,/,
including/VBG
an/DT
Axiom/JJ
Genome-Wide/NN
ASI/NN
1/CD
Array/NN
Plate/NN
and/CC
reagent/JJ
kit/NN
,/,
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
protocol/NN
(/(
Affymetrix/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
Briefly/RB
,/,
total/JJ
genomic/JJ
DNA/NN
(/(
200/CD
ng/NN
)/)
was/VBD
treated/VBN
with/IN
20/CD
µL/NN
of/IN
denaturation/NN
buffer/NN
and/CC
40/CD
µL/NN
neutralization/NN
buffer/NN
,/,
followed/VBN
by/IN
amplification/NN
for/IN
23/CD
h/NN
using/VBG
320/CD
µL/NN
of/IN
Axiom/JJ
amplification/NN
mix/JJ
./.
====================
Amplified/VBN
DNA/NN
was/VBD
randomly/RB
fragmented/JJ
into/IN
25/CD
to/TO
125/CD
base/NN
pair/NN
(/(
bp/NN
)/)
sizes/VBZ
with/IN
57/CD
µL/NN
of/IN
Axiom/JJ
fragmentation/NN
mix/JJ
at/IN
37℃/CD
for/IN
30/CD
min/NN
,/,
followed/VBN
by/IN
DNA/NN
precipitation/NN
for/IN
DNA/NN
clean-up/NN
and/CC
recovery/NN
./.
====================
DNA/NN
pellets/NNS
were/VBD
dried/VBN
and/CC
resuspended/VBD
with/IN
80/CD
µL/NN
of/IN
hybridization/NN
master/JJ
mix/NN
;/:
3/CD
µL/NN
of/IN
suspended/JJ
sample/NN
was/VBD
kept/IN
for/IN
sample/JJ
qualification/NN
./.
====================
A/DT
hybridization-ready/NN
sample/NN
was/VBD
denatured/VBN
using/VBG
a/DT
PCR/NN
machine/NN
at/IN
95℃/CD
for/IN
20/CD
min/NN
and/CC
48℃/CD
for/IN
3/CD
min/NN
./.
====================
Denatured/JJ
DNA/NN
was/VBD
transferred/VBN
to/TO
a/DT
hybridization/NN
tray/NN
and/CC
loaded/VBD
onto/IN
a/DT
GeneTitan/JJ
MC/NN
with/IN
an/DT
Axiom/JJ
ASI/NN
array/NN
plate/VBP
(/(
Affymetrix/JJ
)/)
./.
====================
Hybridization/NN
continued/JJ
on/IN
the/DT
GeneTitan/NN
for/IN
24/CD
h/NN
,/,
followed/VBN
by/IN
loading/VBG
of/IN
ligation/NN
,/,
staining/NN
,/,
and/CC
stabilization/NN
reagent/JJ
trays/VBZ
into/IN
the/DT
instrument/JJ
./.
====================
After/IN
chip/NN
scanning/NN
,/,
the/DT
cel/JJ
intensity/NN
file/JJ
was/VBD
normalized/VBN
,/,
and/CC
genotype/NN
calling/JJ
was/VBD
done/VBN
using/VBG
Genotyping/JJ
Console/NN
4.1/CD
with/IN
Axiom/JJ
GT1/NN
algorithms/NNS
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
manual/JJ
./.
====================
The/DT
cut-off/JJ
values/NNS
for/IN
data/NNS
quality/NN
control/NN
were/VBD
DISHQC/NN
≥/CD
0.82/CD
for/IN
hybridization/NN
and/CC
QC/NN
call/JJ
rate/NN
≥/CD
97/CD
%/NN
./.
====================
Capture/NN
design/NN
====================
The/DT
30/CD
genes/NNS
known/VBN
to/TO
be/VB
mutated/VBN
in/IN
lung/NN
cancer/NN
were/VBD
chosen/NN
for/IN
targeted/VBN
resequencing/VBG
(/(
Table/JJ
1/CD
)/)
./.
====================
The/DT
701/CD
coding/VBG
regions/NNS
in/IN
30/CD
genes/NNS
covered/VBN
102/CD
kb/NN
according/VBG
to/TO
the/DT
consensus/NN
coding/NN
sequence/NN
(/(
CCDS/NN
)/)
database/NN
./.
====================
Capture/NN
sequences/NNS
to/TO
achieve/VB
redundant/JJ
coverage/NN
over/IN
the/DT
coding/VBG
regions/NNS
were/VBD
chosen/RB
based/VBN
on/IN
length/NN
(/(
100-1,000/CD
bp/NN
)/)
and/CC
GC/NN
content/NN
(/(
20-65/CD
%/NN
)/)
and/CC
to/TO
avoid/VB
repetitive/JJ
genomic/JJ
elements/NNS
in/IN
the/DT
ends/NNS
./.
====================
After/IN
analysis/NN
of/IN
in/FW
silico-digested/JJ
restriction/NN
fragments/NNS
of/IN
the/DT
target/NN
regions/NNS
,/,
the/DT
best/JJS
combinations/NNS
of/IN
restriction/NN
enzymes/NNS
were/VBD
selected/VBN
to/TO
provide/VB
over/IN
99/CD
%/NN
coverage/NN
of/IN
targeted/VBN
bases/NNS
./.
====================
Target/NN
enrichment/JJ
analysis/NN
====================
A/DT
normal/JJ
sample/JJ
(/(
NA17022/NN
)/)
and/CC
two/CD
lung/NN
adenocarcinoma/NN
cell/NN
lines/NNS
(/(
H-1650/NN
and/CC
H-23/NN
)/)
were/VBD
examined/VBN
in/IN
this/DT
study/NN
./.
====================
It/PRP
is/VBZ
reported/VBN
in/IN
the/DT
COSMIC/NN
database/NN
that/DT
the/DT
H-1650/NN
cell/NN
line/NN
has/VBZ
a/DT
deletion/NN
mutation/NN
in/IN
the/DT
EGFR/NN
gene/NN
,/,
while/IN
the/DT
H-23/NN
cell/NN
line/NN
has/VBZ
mutations/NNS
in/IN
the/DT
KRAS/JJ
,/,
STK11/NN
,/,
and/CC
TP53/NN
genes/NNS
./.
====================
After/IN
target/NN
gene/NN
enrichment/JJ
,/,
the/DT
enriched/JJ
DNAs/NNS
were/VBD
analyzed/VBN
using/VBG
qPCR/NN
with/IN
primers/NNS
targeting/VBG
the/DT
regions/NNS
of/IN
interest/NN
,/,
along/IN
with/IN
qPCR/NN
primers/NNS
targeting/VBG
irrelevant/JJ
,/,
non-amplified/JJ
loci/NNS
outside/IN
the/DT
target/NN
regions/NNS
./.
====================
The/DT
correlation/NN
between/IN
the/DT
replicates/NNS
was/VBD
high/JJ
(/(
average/NN
r2/NN
=/JJ
0.97/CD
)/)
,/,
and/CC
the/DT
majority/NN
of/IN
primer/NN
pairs/NNS
clustered/VBN
within/IN
a/DT
range/NN
of/IN
3/CD
Cts/NNS
(/(
threshold/NN
cycle/NN
in/IN
qPCR/NN
)/)
./.
====================
Therefore/RB
,/,
the/DT
enrichment/JJ
was/VBD
highly/RB
reproducible/JJ
,/,
and/CC
the/DT
enrichment/JJ
bias/NNS
was/VBD
minimal/JJ
./.
====================
The/DT
enriched/JJ
DNAs/NNS
showed/VBD
an/DT
average/NN
Ct/NN
of/IN
17/CD
with/IN
the/DT
target/NN
primers/NNS
,/,
while/IN
primer/NN
pairs/NNS
targeting/VBG
loci/NNS
outside/IN
of/IN
the/DT
target/NN
regions/NNS
had/VBD
average/JJ
Cts/NNS
of/IN
33/CD
./.
====================
This/DT
indicated/VBD
that/IN
the/DT
enrichment/JJ
was/VBD
target-specific/JJ
./.
====================
The/DT
average/JJ
specificity/NN
in/IN
the/DT
normal/JJ
samples/NNS
was/VBD
28/CD
%/NN
when/WRB
calculated/VBN
from/IN
the/DT
Ct/JJ
and/CC
amount/NN
of/IN
enriched/JJ
product/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Sequencing/NN
analysis/NN
of/IN
enriched/JJ
DNAs/NNS
====================
To/TO
analyze/VB
the/DT
enriched/JJ
samples/NNS
,/,
we/PRP
sequenced/VBD
the/DT
DNAs/NNS
using/VBG
a/DT
GAIIx/JJ
next-generation/NN
sequencing/NN
instrument/JJ
(/(
Illumina/NN
)/)
and/CC
evaluated/VBD
important/JJ
metrics/NNS
to/TO
consider/VB
actual/JJ
coverage/JJ
,/,
specificity/NN
,/,
and/CC
reproducibility/NN
across/IN
the/DT
targeted/VBN
loci/NNS
./.
====================
On/IN
average/JJ
,/,
4.3/CD
gigabases/VBZ
(/(
Gb/NN
)/)
was/VBD
produced/VBN
per/IN
sample/NN
,/,
and/CC
they/PRP
were/VBD
mapped/VBN
to/TO
the/DT
reference/NN
genome/NN
(/(
NCBI/NN
build/JJ
37/CD
,/,
hg19/NN
)/)
at/IN
a/DT
73-90/CD
%/NN
mapping/VBG
rate/NN
(/(
Table/JJ
3/CD
)/)
./.
====================
The/DT
26-41/CD
%/NN
of/IN
the/DT
uniquely/JJ
mapped/VBD
reads/VBZ
were/VBD
found/VBN
in/IN
the/DT
region/NN
of/IN
interest/NN
,/,
demonstrating/VBG
moderate/JJ
specificity/NN
of/IN
this/DT
approach/NN
./.
====================
The/DT
normal/JJ
sample/JJ
showed/VBD
the/DT
lowest/JJS
mapping/VBG
rate/NN
(/(
73.03/CD
%/NN
)/)
but/CC
the/DT
highest/JJS
specificity/NN
(/(
41.58/CD
%/NN
)/)
,/,
indicating/VBG
that/IN
cancer/NN
genomes/NNS
are/VBP
less/RBR
efficient/JJ
for/IN
exome/JJ
sequencing/NN
due/JJ
to/TO
genomic/JJ
changes/NNS
./.
====================
In/IN
addition/NN
,/,
about/RB
97/CD
%/NN
of/IN
the/DT
targeted/VBN
bases/NNS
were/VBD
covered/VBN
at/IN
more/RBR
than/IN
30×/CD
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
This/DT
high/JJ
depth/NN
coverage/NN
could/MD
allow/VB
us/PRP
to/TO
examine/VB
low-purity/JJ
cancer/NN
samples/NNS
,/,
which/WDT
are/VBP
not/RB
normally/RB
analyzed/VBD
by/IN
Sanger/NN
sequencing/NN
or/CC
genotyping/VBG
tools/NNS
./.
====================
The/DT
actual/JJ
coverage/NN
of/IN
the/DT
normal/JJ
sample/JJ
differed/VBD
,/,
depending/VBG
on/IN
the/DT
gene/NN
./.
====================
The/DT
coverage/JJ
of/IN
most/JJS
target/NN
genes/NNS
was/VBD
more/RBR
than/IN
95/CD
%/NN
at/IN
30×/CD
,/,
but/CC
two/CD
genes/NNS
,/,
CDKN2A/NN
and/CC
LTK/NN
,/,
showed/VBD
low/JJ
coverage/NN
of/IN
75/CD
%/NN
and/CC
84/CD
%/NN
,/,
respectively/RB
(/(
Table/JJ
1/CD
)/)
./.
====================
Using/VBG
the/DT
final/JJ
mapped/VBD
reads/VBZ
,/,
we/PRP
constructed/VBD
a/DT
genomic/JJ
profile/NN
database/NN
for/IN
detecting/VBG
SNVs/NNS
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
and/CC
short/JJ
insertions/NNS
and/CC
deletions/NNS
(/(
INDELs/NNS
)/)
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
In/IN
each/DT
sample/NN
,/,
we/PRP
identified/VBD
81-179/CD
SNVs/NNS
and/CC
50-90/CD
small/JJ
INDELs/NNS
in/IN
target/NN
gene/NN
regions/NNS
(/(
Table/JJ
4/CD
)/)
./.
====================
Cancer/NN
samples/NNS
(/(
H-1650/NN
and/CC
H-23/NN
)/)
showed/VBD
about/IN
twice/RB
as/IN
many/JJ
SNVs/NNS
than/IN
the/DT
normal/JJ
sample/JJ
(/(
NA17022/NN
)/)
./.
====================
By/IN
subtracting/VBG
SNVs/NNS
found/VBN
in/IN
the/DT
SNP/NN
databases/NNS
,/,
we/PRP
identified/VBD
cancer-specific/JJ
somatic/JJ
mutation/NN
candidates/NNS
,/,
and/CC
identical/JJ
somatic/JJ
mutations/NNS
of/IN
the/DT
cancer/NN
cell/NN
lines/NNS
in/IN
the/DT
COSMIC/NN
database/NN
were/VBD
found/VBN
./.
====================
All/DT
previously/RB
known/VBN
somatic/JJ
mutations/NNS
in/IN
the/DT
TP53/NN
,/,
KRAS/JJ
,/,
and/CC
STK11/NN
genes/NNS
of/IN
sample/JJ
H-23/NN
and/CC
in/IN
the/DT
EGFR/NN
gene/NN
of/IN
sample/JJ
H-1650/NN
were/VBD
identified/VBN
in/IN
this/DT
study/NN
(/(
Table/JJ
4/CD
)/)
./.
====================
The/DT
validity/NN
of/IN
the/DT
data/NNS
was/VBD
also/RB
examined/VBN
with/IN
a/DT
genome-wide/JJ
SNP/NN
microarray/NN
,/,
which/WDT
has/VBZ
37/CD
SNPs/NNS
in/IN
the/DT
target/NN
region/NN
(/(
Axiom/NNP
Array/NN
;/:
Affymetrix/JJ
)/)
./.
====================
The/DT
genotyping/JJ
data/NNS
showed/VBD
80-91/CD
%/NN
concordance/NN
without/IN
any/DT
bias/NNS
(/(
Table/JJ
5/CD
)/)
./.
====================
The/DT
disconcordant/JJ
variations/NNS
were/VBD
not/RB
biased/VBN
to/TO
any/DT
sample/JJ
,/,
coverage/VBP
,/,
or/CC
genotype/NN
./.
====================
Our/PRP$
targeted/VBN
resequencing/VBG
method/NN
for/IN
somatic/JJ
mutation/NN
profiling/VBG
in/IN
lung/NN
cancer/NN
from/IN
30/CD
cancer-related/JJ
genes/NNS
produced/VBN
unbiased/JJ
target/NN
DNAs/NNS
repeatedly/RB
./.
====================
Analysis/NN
of/IN
the/DT
enriched/JJ
DNAs/NNS
by/IN
next-generation/NN
sequencing/NN
identified/VBN
previously/RB
known/VBN
mutations/NNS
in/IN
the/DT
samples/NNS
./.
====================
Further/RB
analysis/NN
of/IN
more/RBR
samples/NNS
by/IN
targeted/VBN
resequencing/VBG
will/MD
reveal/VB
many/JJ
novel/JJ
variant/JJ
candidates/NNS
./.
====================
Target/NN
enrichment/JJ
was/VBD
performed/VBN
using/VBG
Selector/NN
technology/NN
(/(
Halo/JJ
Genomics/NNS
,/,
Uppsala/NNP
,/,
Sweden/JJ
)/)
,/,
which/WDT
showed/VBD
improved/JJ
coverage/NN
and/CC
compatibility/NN
with/IN
next-generation/NN
sequencing/NN
library/NN
construction/NN
by/IN
employing/VBG
rolling-circle/NN
amplification/NN
[/(
10/CD
]/)
./.
====================
This/DT
method/NN
exhibited/VBD
about/RB
97/CD
%/NN
mean/JJ
coverage/NN
at/IN
30×/CD
depth/NN
,/,
average/JJ
42/CD
%/NN
specificity/NN
,/,
and/CC
high/JJ
reproducibility/NN
(/(
r2/NN
=/JJ
0.98/CD
)/)
of/IN
target/NN
enrichment/JJ
in/IN
the/DT
normal/JJ
sample/JJ
(/(
Tables/NNS
1/CD
,/,
2/CD
,/,
3/CD
)/)
,/,
indicating/VBG
that/IN
this/DT
is/VBZ
applicable/JJ
to/TO
targeted/VBN
resequencing/VBG
of/IN
clinical/JJ
samples/NNS
./.
====================
Although/IN
the/DT
enrichment/JJ
specificity/NN
was/VBD
moderate/JJ
,/,
this/DT
was/VBD
overcome/VBN
by/IN
increasing/VBG
sequencing/NN
depth/NN
./.
====================
As/IN
the/DT
total/JJ
DNA/NN
bases/NNS
of/IN
the/DT
target/NN
regions/NNS
was/VBD
107/CD
kb/NN
,/,
97/CD
%/NN
coverage/NN
at/IN
30×/CD
depth/NN
was/VBD
achieved/VBN
by/IN
3.25/CD
Gb/NN
of/IN
sequencing/NN
,/,
which/WDT
does/VBZ
not/RB
create/VB
any/DT
cost/JJ
issues/NNS
by/IN
using/VBG
next-generation/JJ
sequencing/NN
technologies/NNS
./.
====================
Exome/DT
resequencing/VBG
has/VBZ
proven/VBN
to/TO
be/VB
robust/JJ
and/CC
effective/JJ
for/IN
somatic/JJ
variant/JJ
detection/NN
in/IN
coding/VBG
regions/NNS
[/(
31/CD
,/,
32/CD
]/)
./.
====================
Comparisons/NNS
of/IN
sequencing/NN
data/NNS
from/IN
normal/JJ
and/CC
cancer/NN
tissues/NNS
from/IN
individual/JJ
patients/NNS
have/VBP
unveiled/VBN
individual/JJ
somatic/JJ
mutation/NN
profiles/NNS
./.
====================
However/RB
,/,
the/DT
cancer/NN
cell/NN
lines/NNS
that/WDT
we/PRP
used/VBD
had/VBD
no/DT
normal/JJ
cell/NN
pairs/NNS
./.
====================
To/TO
solve/VB
this/DT
problem/NN
,/,
we/PRP
tried/VBD
to/TO
remove/VB
previously/RB
known/VBN
normal/JJ
variations/NNS
as/IN
much/RB
as/IN
possible/JJ
./.
====================
Predicted/VBN
SNVs/NNS
from/IN
the/DT
sequencing/NN
data/NNS
were/VBD
further/RBR
filtered/JJ
using/VBG
common/JJ
variation/NN
information/NN
from/IN
the/DT
most/JJS
updated/VBN
dbSNP/NN
database/NN
./.
====================
As/IN
a/DT
result/NN
,/,
we/PRP
found/VBD
many/JJ
somatic/JJ
mutations/NNS
,/,
which/WDT
included/VBD
previously/RB
reported/VBN
mutations/NNS
in/IN
the/DT
COSMIC/NN
database/NN
,/,
such/JJ
as/IN
variations/NNS
in/IN
TP53/NN
,/,
KRAS/JJ
,/,
and/CC
STK11/NN
of/IN
sample/JJ
H-23/NN
and/CC
in/IN
EGFR/NN
of/IN
sample/JJ
H-1650/NN
(/(
Table/JJ
4/CD
)/)
./.
====================
Especially/RB
,/,
the/DT
number/NN
of/IN
reads/VBZ
that/DT
covered/VBD
the/DT
four/CD
variations/NNS
was/VBD
more/RBR
than/IN
1,000/CD
./.
====================
This/DT
provides/VBZ
many/JJ
advantages/NNS
when/WRB
compared/VBN
to/TO
whole-genome/DT
sequencing/NN
or/CC
whole-exome/JJ
sequencing/NN
./.
====================
Sequencing/NN
of/IN
cancer/NN
samples/NNS
has/VBZ
raised/VBN
several/JJ
issues/NNS
,/,
such/JJ
as/IN
sample/JJ
purity/NN
and/CC
cancer/NN
heterogeneity/NN
./.
====================
These/DT
shortcomings/NNS
can/MD
only/RB
be/VB
overcome/VBN
by/IN
in-depth/FW
sequencing/NN
of/IN
target/NN
regions/NNS
./.
====================
Therefore/RB
,/,
our/PRP$
protocol/NN
is/VBZ
also/RB
useful/JJ
for/IN
cost-effective/JJ
somatic/JJ
mutation/NN
screening/NN
of/IN
admixed/JJ
clinical/JJ
cancer/NN
samples/NNS
./.
====================
Compared/VBN
to/TO
whole-genome/DT
sequencing/NN
,/,
targeted/VBN
sequencing/NN
has/VBZ
an/DT
issue/NN
with/IN
uneven/JJ
coverage/NN
of/IN
targeted/VBN
genes/NNS
./.
====================
In/IN
Table/JJ
3/CD
,/,
cancer/NN
samples/NNS
showed/VBD
fewer/JJR
sequencing/NN
reads/VBZ
at/IN
target/NN
regions/NNS
./.
====================
This/DT
low/JJ
target/NN
capture/NN
efficiency/NN
in/IN
cancer/NN
samples/NNS
could/MD
be/VB
explained/VBN
by/IN
genetic/JJ
variations/NNS
in/IN
cancer/NN
genomes/NNS
that/IN
inhibit/VBP
the/DT
hybridization/NN
between/IN
cancer/NN
DNA/NN
fragments/NNS
and/CC
the/DT
designed/VBN
capture/NN
oligonucleotides/NNS
./.
====================
This/DT
may/MD
be/VB
overcome/VBN
by/IN
trial-and-error/NN
screening/NN
in/IN
selecting/VBG
more/RBR
efficient/JJ
oligonucleotides/NNS
./.
====================
There/EX
are/VBP
two/CD
kinds/NNS
of/IN
target/NN
capture/NN
technologies/NNS
:/:
hybridization/NN
and/CC
PCR/NN
./.
====================
Hybridization-based/VBN
target/NN
capture/NN
has/VBZ
been/VBN
widely/RB
used/VBN
and/CC
is/VBZ
able/JJ
to/TO
cover/VB
more/RBR
target/NN
regions/NNS
but/CC
is/VBZ
time-consuming/JJ
and/CC
hard/VBP
to/TO
handle/VB
with/IN
many/JJ
samples/NNS
./.
====================
In/IN
contrast/NN
,/,
the/DT
PCR-based/JJ
method/NN
is/VBZ
faster/JJR
and/CC
allows/VBZ
us/PRP
to/TO
handle/NN
more/RBR
samples/NNS
./.
====================
Our/PRP$
protocol/NN
is/VBZ
a/DT
multiple/JJ
displacement/JJ
amplification-based/VBN
method/NN
that/DT
is/VBZ
as/IN
efficient/JJ
as/IN
the/DT
PCR-based/JJ
method/NN
./.
====================
For/IN
example/NN
,/,
hybridization-based/VBD
target/NN
capture/NN
methods/NNS
,/,
such/JJ
as/IN
the/DT
Agilent/JJ
SureSelect/NN
target/NN
enrichment/JJ
kit/NN
and/CC
NimbleGen/NN
SeqCap/NN
EZ/NN
kit/NN
,/,
normally/RB
handle/NN
1-8/CD
samples/NNS
at/IN
the/DT
same/JJ
time/NN
,/,
while/IN
our/PRP$
protocol/NN
with/IN
a/DT
liquid/JJ
handler/NN
could/MD
process/VB
96/CD
samples/NNS
in/IN
parallel/JJ
./.
====================
This/DT
costs/VBZ
12/CD
times/NNS
less/RBR
money/JJ
./.
====================
Therefore/RB
,/,
our/PRP$
target/NN
enrichment/JJ
is/VBZ
scalable/JJ
and/CC
easy/RB
to/TO
handle/NN
with/IN
multiple/JJ
samples/NNS
./.
====================
This/DT
can/MD
result/VB
in/IN
remarkable/JJ
reduction/NN
of/IN
total/JJ
cost/NN
when/WRB
combined/VBN
with/IN
multiplexed/JJ
next-generation/NN
sequencing/NN
./.
====================
Therefore/RB
,/,
our/PRP$
target/NN
resequencing/VBG
protocol/NN
provides/VBZ
a/DT
scalable/JJ
sample-handling/JJ
tool/NN
for/IN
a/DT
genetic/JJ
variation/NN
study/NN
of/IN
lung/NN
adenocarcinoma/NN
./.
====================
Target/NN
coverage/NN
in/IN
cancer/NN
and/CC
normal/JJ
samples/NNS
./.
====================
The/DT
cumulative/JJ
coverage/VBP
of/IN
targeted/VBN
bases/NNS
(/(
i.e./FW
,/,
the/DT
fraction/NN
of/IN
all/DT
sequenced/VBN
bases/NNS
in/IN
the/DT
target/NN
regions/NNS
that/IN
share/VBP
more/RBR
than/IN
a/DT
particular/JJ
read/RB
depth/NN
)/)
were/VBD
plotted/VBN
after/IN
sequencing/VBG
4.34/CD
Gb/NN
of/IN
H-1650/NN
(/(
black/JJ
)/)
,/,
6.03/CD
Gb/NN
of/IN
H-23/NN
(/(
blue/JJ
)/)
,/,
and/CC
3.25/CD
Gb/NN
of/IN
NA17022/NN
(/(
red/JJ
)/)
./.
====================
The/DT
sequencing/NN
yield/VB
in/IN
the/DT
three/CD
samples/NNS
resulted/VBD
in/IN
30×/CD
coverage/NN
of/IN
92/CD
%/NN
(/(
H-1650/NN
)/)
,/,
95/CD
%/NN
(/(
H-23/NN
)/)
,/,
and/CC
97/CD
%/NN
(/(
NA17022/NN
)/)
of/IN
all/DT
target/NN
regions/NNS
./.
====================
30×/CD
coverage/NN
of/IN
individual/JJ
target/NN
genes/NNS
after/IN
deep/NN
sequencing/NN
====================
Target/NN
capture/NN
specificity/NN
analyzed/VBD
by/IN
qPCR/NN
====================
Mapping/NN
statistics/NNS
of/IN
next-generation/NN
sequencing/NN
experiments/NNS
====================
Somatic/JJ
variation/NN
candidates/NNS
from/IN
the/DT
target/NN
gene/NN
regions/NNS
====================
Comparison/NN
of/IN
SNV/NN
calls/NNS
with/IN
DNA/NN
microarray/NN
genotyping/VBG
results/VBZ
====================
